Advarra’s Post

View organization page for Advarra, graphic

46,355 followers

Have you caught up on the new FDA Diversity Action Plan? At a high level, the Diversity Action Plan aims to increase enrollment and retention of clinically relevant study populations in clinical research by ensuring adequate representation of study participants that reflect different age groups, geographic locations, gender identities, sexual orientations, socioeconomic statuses, physical and mental disabilities, and more. Advarra's Luke Gelinas recently weighed in on the potential impact FDA guidance will have on the industry, along with fellow experts Pamela Tenaerts, MD, MBA (Medable) and Pam D. (Curavit). Watch or read their interview here in Applied Clinical Trials Magazine: https://lnkd.in/ekihe6Dx #ClinicalResearch #ClinicalTrials #DEI

  • No alternative text description for this image
April Smith, CCRP, CIP

Human Subjects Research Protection Expert

2w

The FDA's Diversity Action Plan will help to ensure that clinical research is stronger, through well-rounded equitable data, outcomes, solutions, and better treatment options. It is time to make the advancement of healthcare beneficial for everyone.

To view or add a comment, sign in

Explore topics